Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Item
http://www.wikidata.org/entity/Q38767492
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategySecond-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.Quality Assessment of Reporting Performance for EGFR Molecular Diagnosis in Non-Small Cell Lung Cancer.Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.The non-small cell lung cancer EGFR extracellular domain mutation, M277E, is oncogenic and drug-sensitive.Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.EGFR L861Q Mutation in a Metastatic Solid-pseudopapillary Neoplasm of the Pancreas.EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistanceSensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
P2860

Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?

Item
http://www.wikidata.org/entity/Q38767492
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Sensitivities to various epide ...... tor-tyrosine kinase inhibitor?
@en
type
label
Sensitivities to various epide ...... tor-tyrosine kinase inhibitor?
@en
prefLabel
Sensitivities to various epide ...... tor-tyrosine kinase inhibitor?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Sensitivities to various epide ...... tor-tyrosine kinase inhibitor?
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932